OSHKOSH, Wis., April 8, 2019 /PRNewswire/ — Bemis Healthcare Packaging recently launched Insura™, an innovative seal verification technology designed specifically for medical device packaging. This technology is a real-time, non-destructive visual indicator of seal quality which is imbedded into the sterile barrier system. A blue color is generated under only proper seal conditions – chemistry, heat and intimate contact.
“Collaborating with our customers and understanding their needs in this quality driven market led us to develop this exciting, game changing technology,” said Bemis Healthcare Packaging’s Marketing Manager, David Vanden Heuvel.
Successfully engineering this technology platform was enabled by Bemis’s material science expertise.
To discuss how Insura™ Seal Verification can benefit your organization, contact Bemis Healthcare Packaging at bhp@bemis.com.
ABOUT BEMIS HEALTHCARE PACKAGING Bemis Healthcare Packaging specializes in the manufacture of coextruded, laminated, and flexible forming films, foil barrier laminations, pouches, bags, thermoformed trays, lids, heat seal coating and medical grades of paper. Locations include Oshkosh, WI; New London, WI; Mankato, MN; Carolina, Puerto Rico; Suzhou, China, and Selangor, Malaysia.
ABOUT BEMIS COMPANY, INC. Bemis creates exceptional packaging for food, consumer product, healthcare, and industrial applications. Bemis reported 2017 net sales of $4.0 billion. Bemis has a strong technical base in polymer chemistry, film extrusion, coating and laminating, printing, and converting. Founded in 1858, and today headquartered in Neenah, Wisconsin, Bemis employs approximately 16,500 individuals worldwide. More information about Bemis is available at www.bemis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/bemis-healthcare-packaging-launches-insura-seal-verification-technology-300825636.html
SOURCE Bemis Healthcare Packaging
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…